FDA Panel Addresses Future Uterine Fibroid Treatment Studies
This article was originally published in The Gray Sheet
Executive Summary
Improvements in a patient's quality of life and bleeding should be sufficient measures to gauge the safety and effectiveness of new treatments for symptomatic uterine fibroids, an FDA advisory panel recommends